The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 3 rounds in the feed, most often in Biotech.
TCG Crossover (“TCGX”) is a science-driven investment firm dedicated to advancing disruptive medicines.
Venture capitaltcgcrossover.comRounds from 2026-01-22 to ~ 2026-10-10
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Soufflé Therapeutics A leading RNA therapies company aimed at advancing the next generation of therapies designed to help people live healthier lives | Series B Verified against 1 of 29 sources | $135M | ~ 2026-10-10 | [ PART ] |
TriGemX Bio A biotechnology company focused on developing a medicines for the treatment of migraine | Funding round |
| $94M |
| 2026-10-01 |
| [ LEAD ] |
CORXEL Pharmaceuticals Innovative therapies for cardiometabolic diseases, targeting conditions such as obesity and Type 2 Diabetes Mellitus. | Series D+ Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $287M | 2026-01-22 | [ PART ] |